Celldex Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Celldex Therapeutics has a total shareholder equity of $429.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $465.6M and $36.5M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$423.60m |
Equity | US$429.17m |
Total liabilities | US$36.46m |
Total assets | US$465.63m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: TCE2's short term assets ($431.7M) exceed its short term liabilities ($31.1M).
Long Term Liabilities: TCE2's short term assets ($431.7M) exceed its long term liabilities ($5.3M).
Debt to Equity History and Analysis
Debt Level: TCE2 is debt free.
Reducing Debt: TCE2 had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TCE2 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: TCE2 has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of 6.1% each year.